**PRODUCT INFORMATION**

**BPIPP**

*Item No. 21675*

---

**CAS Registry No.:** 325746-94-9  
**Formal Name:** 5-(3-bromophenyl)-5,11-dihydro-1,3-dimethyl-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione  
**MF:** C_{22}H_{16}BrN_{3}O_{3}  
**FW:** 450.3  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

---

**Laboratory Procedures**

BPIPP is supplied as a solid. A stock solution may be made by dissolving the BPIPP in the solvent of choice, which should be purged with an inert gas. BPIPP is slightly soluble in DMSO and methanol.

---

**Description**

BPIPP is a non-competitive inhibitor of guanylyl and adenyl cyclases that suppresses cGMP accumulation induced by stable toxin (STa), guanylin, atrial natriuretic peptide (Item Nos. 24539 | 24276), and C-type natriuretic peptide (Item No. 24401) in vitro (IC_{50}s = 3.4-11.2 μM). It inhibits chloride efflux induced by STa, forskolin (Item No. 11018), cholera toxin (Item No. 19654), and isoproterenol (Item No. 15592) in T84 cells but has no effect on basal chloride efflux. BPIPP (10 or 50 μM) suppresses STa-induced liquid secretion in a rabbit intestinal loop model of toxin-induced secretory diarrhea.

---

**Reference**